The purpose of this clinical study is to develop a new vaccine that may prevent Mpox (previously known as monkeypox) and smallpox. This clinical study will test the investigational vaccine, known as mRNA-1769. This study will compare mRNA-1769 to a placebo. A placebo looks like mRNA-1769 but has no active drug.
Researchers will measure your immune response to the investigational vaccine by collecting blood samples to check for natural proteins called antibodies and other aspects of your immune response to the investigational vaccine. Checking your antibody levels informs researchers of how well the investigational vaccine may work against the virus. The trial doctors and team will monitor your health throughout your participation.
Who can participate?
You may be able to participate if you:
- Are between the ages of 18 and 49
- Are in generally good health
- Have a body mass index (BMI) from ≥18 kg/m2 and ≤39 kg/m2
- Have NOT previously received a smallpox vaccination or any other poxvirus-based vaccination
- Have NOT, to your knowledge, been recently exposed to mpox virus
How long will I be in the trial?
Participation in this trial will last around 13-14 months and includes 1 screening visit, 8 additional visits to the trial site and 3 safety phone calls.
Compensation for your time
Participants will receive compensation for their trial-related time and travel to UCLH Clinical Research Facility.
The study is being led at the NIHR UCLH Clinical Research Facility by Professor Vincenzo Libri.
To learn more and to see if you qualify for this important study please email UCLH.mRNAmonkeypox@nhs.net.
